The X-ray crystal structure data of 12-α-fluoro-3β-hy­droxy­olean-28,13β-olide methanol hemisolvate, 2C30H47FO3·CH3OH, (1), and 12-α-fluoro-3β-hy­droxy­taraxer-28,14β-olide methanol hemisolvate, 2C30H47FO3·CH3OH, (2), are described. The fluoro­lactonization of oleanolic acid using SelectfluorTM yielded a mixture of the six-membered δ-lactone (1) and the unusual seven-membered γ-lactone (2) following a 1,2-shift of methyl C-27 from C-14 to C-13.

In the title salt, C6H16N22+ ·H2P2O72−, the complete dication is generated by a crystallographic centre of symmetry with the methyl groups in equatorial orientations. The complete dianion is generated by a crystallographic twofold axis with the central O atom lying on the axis: the P—O—P bond angle is 135.50 (12)°. In the crystal, the di­hydrogen diphosphate anions are linked by O—H⋯O hydrogen bonds, generating (001) layers. The organic cations bond to the inorganic layers by way of N—H⋯O and C—H⋯O hydrogen bonds. A Hirshfeld surface analysis shows that the most important contributions for the crystal packing are from O⋯H/H⋯O (60.5%) and H⋯H (39.4%) contacts.

The observation of neutron interference using a triple Laue interferometer formed by two separate crystals opens the way to the construction and operation of skew-symmetric interferometers with extended arm separation and length. The specifications necessary for their successful operation are investigated here: most importantly, how the manufacturing tolerance and crystal alignments impact the interference visibility. In contrast with previous studies, both incoherent sources and the three-dimensional operation of the interferometer are considered. It is found that, with a Gaussian Schell model of an incoherent source, the integrated density of the particles leaving the interferometer is the same as that yielded by a coherent Gaussian source having a radius equal to the coherence length.

Hendrickson & Lattman [Acta Cryst. (1970), B26, 136–143] introduced a method for representing crystallographic phase probabilities defined on the unit circle. Their approach could model the bimodal phase probability distributions that can result from experimental phase determination procedures. It also provided simple and highly effective means to combine independent sources of phase information. The present work discusses the equivalence of the Hendrickson–Lattman distribution and the generalized von Mises distribution of order two, which has been studied in the statistical literature. Recognizing this connection allows the Hendrickson–Lattman distribution to be expressed in an alternative form which is easier to interpret, as it involves the location and concentration parameters of the component von Mises distributions. It also allows clarification of the conditions for bimodality and access to a simplified analytical method for evaluating the trigonometric moments of the distribution, the first of which is required for computing the best Fourier synthesis in the presence of phase, but not amplitude, uncertainty.

Fluctuation X-ray scattering (FXS) offers a complementary approach for nano- and bioparticle imaging with an X-ray free-electron laser (XFEL), by extracting structural information from correlations in scattered XFEL pulses. Here a workflow is presented for single-particle structure determination using FXS. The workflow includes procedures for extracting the rotational invariants from FXS patterns, performing structure reconstructions via iterative phasing of the invariants, and aligning and averaging multiple reconstructions. The reconstruction pipeline is implemented in the open-source software xFrame and its functionality is demonstrated on several simulated structures.

A systematic procedure is introduced for modeling charge-neutral non-polar surfaces of ionic minerals containing polyatomic anions. By integrating distance- and charge-based clustering to identify chemical species within the mineral bulk, our pipeline, PolyCleaver, renders a variety of theoretically viable surface terminations. As a demonstrative example, this approach was applied to forsterite (Mg2SiO4), unveiling a rich interface landscape based on interactions with formaldehyde, a relevant multifaceted molecule, and more particularly in prebiotic chemistry. This high-throughput method, going beyond techniques traditionally applied in the modeling of minerals, offers new insights into the potential catalytic properties of diverse surfaces, enabling a broader exploration of synthetic pathways in complex mineral systems.

The strong metal–support interaction (SMSI) is a phenomenon observed in supported metal catalyst systems in which reducible metal oxide supports can form overlayers over the surface of active metal nanoparticles (NPs) under a hydrogen (H2) environment at elevated temperatures. SMSI has been shown to affect catalyst performance in many reactions by changing the type and number of active sites on the catalyst surface. Laboratory methods for the analysis of SMSI at the nanoparticle-ensemble level are lacking and mostly based on indirect evidence, such as gas chemisorption. Here, we demonstrate the possibility to detect and characterize SMSIs in Co/TiOx model catalysts using the laboratory X-ray standing wave (XSW) technique for a large ensemble of NPs at the bulk scale. We designed a thermally stable MoNx/SiNx periodic multilayer to retain XSW generation after reduction with H2 gas at 600°C. The model catalyst system was synthesized here by deposition of a thin TiOx layer on top of the periodic multilayer, followed by Co NP deposition via spare ablation. A partial encapsulation of Co NPs by TiOx was identified by analyzing the change in Ti atomic distribution. This novel methodological approach can be extended to observe surface restructuring of model catalysts in situ at high temperature (up to 1000°C) and pressure (≤3 mbar), and can also be relevant for fundamental studies in the thermal stability of membranes, as well as metallurgy.

Polymer-derived ceramics (PDCs) remain at the forefront of research for a variety of applications including ultra-high-temperature ceramics, energy storage and functional coatings. Despite their wide use, questions remain about the complex structural transition from polymer to ceramic and how local structure influences the final microstructure and resulting properties. This is further complicated when nanofillers are introduced to tailor structural and functional properties, as nanoparticle surfaces can interact with the matrix and influence the resulting structure. The inclusion of crystalline nanofiller produces a mixed crystalline–amorphous composite, which poses characterization challenges. With this study, we aim to address these challenges with a local-scale structural study that probes changes in a polysiloxane matrix with incorporated copper nanofiller. Composites were processed at three unique temperatures to capture mixing, pyrolysis and initial crystallization stages for the pre-ceramic polymer. We observed the evolution of the nanofiller with electron microscopy and applied synchrotron X-ray diffraction with differential pair distribution function (d-PDF) analysis to monitor changes in the matrix's local structure and interactions with the nanofiller. The application of the d-PDF to PDC materials is novel and informs future studies to understand interfacial interactions between nanofiller and matrix throughout PDC processing.

The influence of various combinations of residual stress, composition and grain interaction gradients in polycrystalline materials with cubic symmetry on energy-dispersive X-ray stress analysis is theoretically investigated. For the evaluation of the simulated sin2ψ distributions, two different strategies are compared with regard to their suitability for separating the individual gradients. It is shown that the separation of depth gradients of the strain-free lattice parameter a0(z) from residual stress gradients σ(z) is only possible if the data analysis is carried out in section planes parallel to the surface. The impact of a surface layer z* that is characterized by a direction-dependent grain interaction model in contrast to the volume of the material is quantified by comparing a ferritic and an austenitic steel, which feature different elastic anisotropy. It is shown to be of minor influence on the resulting residual stress depth profiles if the data evaluation is restricted to reflections hkl with orientation factors Γhkl close to the model-independent orientation Γ*. Finally, a method is proposed that allows the thickness of the anisotropic surface layer z* to be estimated on the basis of an optimization procedure.

Structural modelling of operando pair distribution function (PDF) data of complex functional materials can be highly challenging. To aid the understanding of complex operando PDF data, this article demonstrates a toolbox for PDF analysis. The tools include denoising using principal component analysis together with the structureMining, similarityMapping and nmfMapping apps available through the online service `PDF in the cloud' (PDFitc, https://pdfitc.org/). The toolbox is used for both ex situ and operando PDF data for 3 nm TiO2-bronze nanocrystals, which function as the active electrode material in a Li-ion battery. The tools enable structural modelling of the ex situ and operando PDF data, revealing two pristine TiO2 phases (bronze and anatase) and two lithiated LixTiO2 phases (lithiated versions of bronze and anatase), and the phase evolution during galvanostatic cycling is characterized.

Ptychography is a powerful computational imaging technique with microscopic imaging capability and adaptability to various specimens. To obtain an imaging result, it requires a phase-retrieval algorithm whose performance directly determines the imaging quality. Recently, deep neural network (DNN)-based phase retrieval has been proposed to improve the imaging quality from the ordinary model-based iterative algorithms. However, the DNN-based methods have some limitations because of the sensitivity to changes in experimental conditions and the difficulty of collecting enough measured specimen images for training the DNN. To overcome these limitations, a ptychographic phase-retrieval algorithm that combines model-based and DNN-based approaches is proposed. This method exploits a DNN-based denoiser to assist an iterative algorithm like ePIE in finding better reconstruction images. This combination of DNN and iterative algorithms allows the measurement model to be explicitly incorporated into the DNN-based approach, improving its robustness to changes in experimental conditions. Furthermore, to circumvent the difficulty of collecting the training data, it is proposed that the DNN-based denoiser be trained without using actual measured specimen images but using a formula-driven supervised approach that systemically generates synthetic images. In experiments using simulation based on a hard X-ray ptychographic measurement system, the imaging capability of the proposed method was evaluated by comparing it with ePIE and rPIE. These results demonstrated that the proposed method was able to reconstruct higher-spatial-resolution images with half the number of iterations required by ePIE and rPIE, even for data with low illumination intensity. Also, the proposed method was shown to be robust to its hyperparameters. In addition, the proposed method was applied to ptychographic datasets of a Simens star chart and ink toner particles measured at SPring-8 BL24XU, which confirmed that it can successfully reconstruct images from measurement scans with a lower overlap ratio of the illumination regions than is required by ePIE and rPIE.

Energy-dispersive Laue diffraction (EDLD) is a powerful method to obtain position-resolved texture information in inhomogeneous biological samples without the need for sample rotation. This study employs EDLD texture scanning to investigate the impact of two salivary peptides, statherin (STN) and histatin-1 (HTN) 21 N-terminal peptides (STN21 and HTN21), on the crystallographic structure of dental enamel. These proteins are known to play crucial roles in dental caries progression. Three healthy incisors were randomly assigned to three groups: artificially demineralized, demineralized after HTN21 peptide pre-treatment and demineralized after STN21 peptide pre-treatment. To understand the micro-scale structure of the enamel, each specimen was scanned from the enamel surface to a depth of 250 µm using microbeam EDLD. Via the use of a white beam and a pixelated detector, where each pixel functions as a spectrometer, pole figures were obtained in a single exposure at each measurement point. The results revealed distinct orientations of hydroxyapatite crystallites and notable texture variation in the peptide-treated demineralized samples compared with the demineralized control. Specifically, the peptide-treated demineralized samples exhibited up to three orientation populations, in contrast to the demineralized control which displayed only a single orientation population. The texture index of the demineralized control (2.00 ± 0.21) was found to be lower than that of either the STN21 (2.32 ± 0.20) or the HTN21 (2.90 ± 0.46) treated samples. Hence, texture scanning with EDLD gives new insights into dental enamel crystallite orientation and links the present understanding of enamel demineralization to the underlying crystalline texture. For the first time, the feasibility of EDLD texture measurements for quantitative texture evaluation in demineralized dental enamel samples is demonstrated.

A procedure is presented to exactly obtain the apparent average crystallite size (ACS) of powder samples using standard in-house powder diffraction experiments without any restriction originating from the Scherrer equation. Additionally, the crystallite size distribution within the sample can be evaluated. To achieve this, powder diffractograms are background corrected and long-range radial distribution functions G(r) up to 300 nm are calculated from the diffraction data. The envelope function fenv of G(r) is approximated by a procedure determining the absolute maxima of G(r) in a certain interval (r range). Fitting of an ACS distribution envelope function to this approximation gives the ACS and its distribution. The method is tested on diffractograms of LaB6 standard reference materials measured with different wavelengths to demonstrate the validity of the approach and to clarify the influence of the wavelength used. The latter results in a general description of the maximum observable average crystallite size, which depends on the instrument and wavelength used. The crystallite site distribution is compared with particle size distributions based on transmission electron microscopy investigations, providing an approximation of the average number of crystallites per particle.

Understanding the structure–property relationship in electrocatalysts under working conditions is crucial for the rational design of novel and improved catalytic materials. This paper presents the Aarhus University reactor for electrochemical studies using X-rays (AUREX) operando electrocatalytic flow cell, designed as an easy-to-use versatile setup with a minimal background contribution and a uniform flow field to limit concentration polarization and handle gas formation. The cell has been employed to measure operando total scattering, diffraction and absorption spectroscopy as well as simultaneous combinations thereof on a commercial silver electrocatalyst for proof of concept. This combination of operando techniques allows for monitoring of the short-, medium- and long-range structure under working conditions, including an applied potential, liquid electrolyte and local reaction environment. The structural transformations of the Ag electrocatalyst are monitored with non-negative matrix factorization, linear combination analysis, the Pearson correlation coefficient matrix, and refinements in both real and reciprocal space. Upon application of an oxidative potential in an Ar-saturated aqueous 0.1 M KHCO3/K2CO3 electrolyte, the face-centered cubic (f.c.c.) Ag gradually transforms first to a trigonal Ag2CO3 phase, followed by the formation of a monoclinic Ag2CO3 phase. A reducing potential immediately reverts the structure to the Ag (f.c.c.) phase. Following the electrochemical-reaction-induced phase transitions is of fundamental interest and necessary for understanding and improving the stability of electrocatalysts, and the operando cell proves a versatile setup for probing this. In addition, it is demonstrated that, when studying electrochemical reactions, a high energy or short exposure time is needed to circumvent beam-induced effects.

The two most abundant CaCO3 polymorphs, calcite and aragonite, are universally recognized for the richness of their morphology to which different twins make relevant contributions. The epitaxial transformation calcite ↔ aragonite has long been debated. While the twinning has been thoroughly treated, the homo-epitaxy occurring within each of these minerals has, inexplicably, been overlooked to date, both experimentally and theoretically. Twinning can be deceptive to the point where it can be mistaken for homo-epitaxy, thus making the proposed growth mechanism in the crystal aggregate wrong. Within the present work, the first aim is a theoretical investigation of the homo-epitaxies among the three {10.4}-cleavage, {01.2}-steep and {01.8}-flat rhombohedra of calcite. Accordingly, the specific adhesion energies were calculated between facing crystal forms, unequivocally showing that the {01.2}/{01.8} homo-epitaxy competes with the generation of both {01.2} and {01.8} contact twins. Secondly, the calculation of the specific adhesion energy was extended to consider homo-epitaxy for the {10.4} rhombohedron. The two-dimensional geometric lattice coincidence has been tried for the {00.1} pinacoidal form as well.

The upgrade of the Swiss Light Source, called SLS 2.0, necessitates comprehensive updates to all 18 user front ends. This upgrade is driven by the increased power of the synchrotron beam, reduced floor space, changing source points, new safety regulations and enhanced beam properties, including a brightness increase by up to a factor of 40. While some existing front-end components are being thoroughly refurbished and upgraded for safety reasons, other components, especially those designed to tailor the new synchrotron beam, are being completely rebuilt. These new designs feature innovative and enhanced cooling systems to manage the high-power load and meet new requirements such as mechanical stability and compact footprints.

A novel in situ/operando method is introduced to measure the photon beam stability of synchrotron radiation based on orthogonal diffraction imaging of a Laue crystal/analyzer, which can decouple the energy/wavelength and Bragg angle of the photon beam using the dispersion effect in the diffraction process. The method was used to measure the energy jitter and drift of the photon beam on BL09B and BL16U at the Shanghai Synchrotron Radiation Facility. The experimental results show that this method can provide a fast way to measure the beam stability of different light sources including bending magnet and undulator with meV-level energy resolution and ms-level time response.

Autonomous methods to align beamlines can decrease the amount of time spent on diagnostics, and also uncover better global optima leading to better beam quality. The alignment of these beamlines is a high-dimensional expensive-to-sample optimization problem involving the simultaneous treatment of many optical elements with correlated and nonlinear dynamics. Bayesian optimization is a strategy of efficient global optimization that has proved successful in similar regimes in a wide variety of beamline alignment applications, though it has typically been implemented for particular beamlines and optimization tasks. In this paper, we present a basic formulation of Bayesian inference and Gaussian process models as they relate to multi-objective Bayesian optimization, as well as the practical challenges presented by beamline alignment. We show that the same general implementation of Bayesian optimization with special consideration for beamline alignment can quickly learn the dynamics of particular beamlines in an online fashion through hyperparameter fitting with no prior information. We present the implementation of a concise software framework for beamline alignment and test it on four different optimization problems for experiments on X-ray beamlines at the National Synchrotron Light Source II and the Advanced Light Source, and an electron beam at the Accelerator Test Facility, along with benchmarking on a simulated digital twin. We discuss new applications of the framework, and the potential for a unified approach to beamline alignment at synchrotron facilities.

The Australian Synchrotron Imaging and Medical Beamline (IMBL) uses a superconducting multipole wiggler (SCMPW) source, dual crystal Laue monochromator and 135 m propagation distance to enable imaging and computed tomography (CT) studies of large samples with mono-energetic radiation. This study aimed to quantify two methods for CT dose reduction: wiggler source operation at reduced magnetic field strength, and beam modulation with spatial filters placed upstream from the sample. Transmission measurements with copper were used to indirectly quantify the influence of third harmonic radiation. Operation at lower wiggler magnetic field strength reduces dose rates by an order of magnitude, and suppresses the influence of harmonic radiation, which is of significance near 30 keV. Beam shaping filters modulate the incident beam profile for near constant transmitted signal, and offer protection to radio-sensitive surface organs: the eye lens, thyroid and female breast. Their effect is to reduce the peripheral dose and the dose to the scanned volume by about 10% for biological samples of 35–50 mm diameter and by 20–30% for samples of up to 160 mm diameter. CT dosimetry results are presented as in-air measurements that are specific to the IMBL, and as ratios to in-air measurements that may be applied to other beamlines. As CT dose calculators for small animals are yet to be developed, results presented here and in a previous study may be used to estimate absorbed dose to organs near the surface and the isocentre.

Mirakl has announced its partnership with

 ‘The Road Ahead: Towards Seamless Payments Interoperability’, an eBook from Thunes, Visa, and The Paypers, explores how payments interoperability is reshaping the future of cross-border transactions.

The Federal Trade Commission (FTC) has...

The general equation of the δ direct methods is established and applied in its difference form to the definition of one of the two residuals that constitute the SMAR phasing algorithm. These two residuals use the absolute value of ρ and/or the zero conversion of negative Fourier ripples (≥50% of the unit-cell volume). Alternatively, when solved for ρ, the general equation provides a simple derivation of the already known δM tangent formula.

Source: Streetwise Reports 10/28/2024

Atlas Lithium Corp. (ATLX:NASDAQ) announced that it has received the operational permit for its Neves Project. This marks a significant milestone for the company's ambitions in lithium production. The permit, approved by the Minas Gerais government in Brazil, allows Atlas Lithium to assemble and operate its processing plant, develop open-pit mining operations, and produce lithium concentrate. The unanimously voted October 25 decision officially progressed with the publication in Minas Gerais' government gazette the following day.

The Neves Project permit, a comprehensive triphasic license (LI/LP/LO), enables a more streamlined development, encompassing initial, installation, and operating permissions.

"Permitting is widely considered the most critical risk in any mining project," said Atlas Lithium CEO Marc Fogassa in the news release. The company's success in obtaining this permit underscores its commitment to sustainable, responsible operations in Brazil's "Lithium Valley."

The Allure of The Lithium Market

According to Visual Capitalist on September 29, battery metal prices have recently "struggled as a surge in new production overwhelmed demand." However, with battery demand projected to increase ninefold by 2040, companies positioned to produce high-quality lithium concentrate, such as Atlas Lithium, are likely to see enhanced market relevance as the demand trajectory for lithium-ion batteries strengthens significantly over the coming decades.

Jake Sekelsky from Alliance Global Partners reaffirmed his "Buy" rating for Atlas Lithium, setting a price target of US$45.00.

As Forbes wrote on October 8, 2024, recent industry dynamics have shown that "a 50% rise in the price of a downtrodden lithium producer has boosted investor hopes that a revival in the battery metal is possible after two grim years of oversupply and low prices."

This improvement in lithium prices reflects a broader trend that may positively impact companies like Atlas Lithium, whose operational progress aligns with the gradual sector recovery. The recent permitting for Atlas Lithium's Neves Project positions it to capitalize on these trends as it advances its lithium production capabilities.

On that same day, Barry Dawes of Martin Place Securities commented that "the lithium market is showing strong signs of upturn," anticipating "lithium shortages post-2027." This outlook emphasizes the sector's potential for heightened demand and supply constraints, which is particularly beneficial for projects advancing toward production. Atlas Lithium's strategy, which includes a modular processing plant and environmentally responsible operations, underscores the company's readiness to meet this anticipated demand.

What's Driving Atlas Forward?

Atlas Lithium's Neves Project's recent permit positions the company to advance toward its production goals with key environmental and operational clearances in place. According to the company's September 2024 investor presentation, this approval aligns with an expedited project timeline and enhances the company's potential to become a low-cost lithium concentrate producer. With Brazil's favorable mining conditions and Atlas Lithium's established partnerships with Tier 1 global companies, the Neves Project is poised for cost-effective operations and market alignment.

Atlas's modular processing plant, currently in the final pre-shipment stage, also demonstrates a strategic focus on efficiency and ESG standards. This advanced plant is set for rapid assembly and installation. It reflects Atlas Lithium's intention to minimize environmental impact and expedite production ramp-up, contributing to a streamlined path toward production in Brazil's burgeoning lithium sector.

Analysts On Atlas

Jake Sekelsky from Alliance Global Partners reaffirmed his "Buy" rating for Atlas Lithium, setting a price target of US$45.00. He described the recent operational permit issuance for the Neves Project as a "significant de-risking event," emphasizing that this milestone positions the project to move forward with construction and operations. Sekelsky highlighted that the approval "marks the final step in the permitting process" and grants Atlas Lithium the authorization to proceed with assembling its processing facility and initiating open-pit mining operations. This development aligns with a clear production path, with Sekelsky noting that the project is now at "shovel-ready status," a critical advancement toward fulfilling Atlas Lithium's strategic objectives. [OWNERSHIP_CHART-11040]

Sekelsky also pointed to the current market environment for lithium, expressing optimism regarding "signs of an upcoming recovery" in lithium prices. He interpreted recent merger and acquisition activities within the sector, including other acquisitions in Brazil's Lithium Valley, as indicators that larger players anticipate a rebound. Sekelsky remarked that this resurgence could benefit advanced hard-rock lithium projects, such as Neves, which "continue to command attention from potential suitors."

Ownership and Share Structure

About 34% of Atlas Lithium is owned by management and insiders. About 11% of the shareholders are institutional. Strategic partners hold another 12%. The rest, about 43%, is retail.

Top shareholders include Waratah Capital Advisors Ltd. with 4.34%, Mitsui & Co. Ltd. with 12.27%, and Candace Shira Associates LLC with 1.39%, according to Reuters.

Its market cap is about US$165 million. It trades in a 52-week range of US$34 and US$6.25.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: ATLX:NASDAQ, )

Shortly after I published the second post about the Mertens conjecture, a reader's comment suggested a new approach to computing Redheffer determinants and the Mertens function. It is now possible to compute a half-million values of the Mertens function in about five hours.... read more >>

A friend is investigating the use of generative AI in his classes. I asked two different popular chatbots to write MATLAB programs for a mathematically nontrivial problem. Both chatbots understood my query and both wrote plausible MATLAB programs, but one of the programs was not correct. My recommendation for coursework: carefully read and test programs produced by generative AI and repair any incorrect ones.... read more >>

Source: Streetwise Reports 11/06/2024

Golden Cariboo Resources Ltd. (GCC:CSE; GCCFF:OTC; A0RLEP:WKN; 3TZ:FSE) has reported encouraging results from its 2024 field campaign. During the exploration, the company collected 16 rock samples from the Halo zone, North Hixon zone, and Pioneer area. These samples revealed promising gold mineralization in the region. Notable highlights from the Halo zone include grab samples from newly exposed outcrops, with assays reaching 8.47 g/t Au (grams per tonne, gold), 6.59 g/t Au, and 2.39 g/t Au. These samples were taken from altered andesite tuff with quartz-carbonate veins located approximately 101 meters northeast of the nearest drill collar.

Sampling near the Pioneer showing, situated one-kilometer north-northwest of the Halo zone, also returned assays of 1.13 g/t Au and 0.40 g/t Au. The fieldwork's findings have significantly extended the strike length of known gold mineralization by one kilometer and expanded the surface footprint of mineralization to the northeast. Despite challenging glacial cover, Golden Cariboo's team continues to uncover significant gold-bearing outcrops.

The report also underscored the strategic advantages of the property's location, infrastructure, and proximity to Highway 97, which reduces exploration and operational costs. Wortel detailed Golden Cariboo's drilling campaign, which includes results such as Hole QGQ24-013, which intersected 136.51 meters at 1.77 g/t gold, including a higher-grade interval of 23.89 meters at 3.32 g/t gold.

Valuation metrics from the report included a projected fair value of CA$0.40 per share, representing a 74% potential upside from the current trading price of CA$0.23, and doesn't include the added value from recent, significant exploration success. Despite acknowledging the high risks associated with early-stage exploration projects, Couloir Capital emphasized the long-term value potential in a Tier 1 mining jurisdiction, reinforced by the company's experienced management team and promising geological trends.

Frank Callaghan, President and CEO of Golden Cariboo, stated in the news release, "Although there is a lot of glacial cover on this project, our geologists still managed to find new gold-bearing outcrops in areas of great significance. We have now expanded the surface footprint of gold mineralization at the Halo zone to the northeast and increased the strike length of our gold trend. We're in a very large gold system that is being demonstrated by multiple, varied work programs."

Mining and Metals Market

On October 29, Kitco reported that gold prices had reached nearly US$2,800. This price represents a 35% increase for the year. The rise was attributed to multiple factors, including "geopolitical conflicts, Federal Reserve interest rate normalization, continued strong demand from global central banks, and uncertainties about the upcoming presidential election and potential fiscal stimulus." Analysts at Kitco described this combination of elements as a "perfect storm." They noted it had driven investor sentiment and reinforced gold's value as a hedge against economic turmoil.

LiveMint, on October 30, highlighted the substantial returns seen in gold over the past year. Despite this impressive performance, some analysts expressed caution regarding gold's future trajectory. Ajay Kedia, Director of Kedia Advisory, suggested that while gold prices may see a short-term rally, "investors may have to remain cautious on the yellow metal in the second half of 2025." Kedia noted that gold prices could experience profit-taking and a slowdown if interest rate cuts by the Federal Reserve do not materialize as quickly as expected. Nonetheless, gold has continued to serve as a preferred asset for those seeking stability, especially in times of economic and political uncertainty.

In a November 4 report, Egon von Greyerz, Founder and Chairman of Matterhorn Asset Management, provided a historical perspective on gold's role in preserving wealth. Von Greyerz discussed how gold had consistently retained value, even as fiat currencies depreciated over time. He emphasized, "Gold held in the investor's name in safe vaults and jurisdictions outside the financial system is the ultimate form of wealth preservation." Von Greyerz also pointed to gold's outperformance since the 1970s, stating that gold had increased 78 times since President Nixon ended the gold standard in 1971. He argued that gold's journey was "only starting now," citing the ongoing destruction of fiat money value through global debt expansion and monetary policies.

Cariboo Catalysts

According to Golden Cariboo Resources' Q1 2024 investor presentation, the company is advancing exploration on its 3,814-hectare Quesnelle Gold Quartz Mine property, located in British Columbia's historic Cariboo Mining District. The asset benefits from 160 years of mining history and is road-accessible, facilitating year-round exploration. The 2024 exploration program, including trenching and a proposed 2,500-5,000m Phase 2 drilling campaign, aims to delineate the gold system further and complete a National Instrument 43-101 compliant resource estimate.

The property, encircled by Osisko Development Corp. on three sides, holds the potential for high-grade, multi-ounce gold targets. Management is focusing on a multi-phase exploration strategy. This includes trenching to assess shallow overburden and mapping and sampling to refine drill targets. The team's experience and the property's historical and geological significance position Golden Cariboo as a promising exploration venture.

The proposed drilling and development efforts reflect a systematic approach to unlocking value in this underexplored yet historically significant gold camp as the company progresses toward realizing a resource estimate.

Expert Analysis

Golden Cariboo Resources Inc. received favorable coverage from Couloir Capital in a report released on September 3, 2024. Senior Mining Analyst Ron Wortel issued a Buy recommendation for the company, noting the significant potential for discovering a large gold resource at the Quesnelle Gold Quartz property. Wortel highlighted that the property, located in British Columbia's historic Cariboo Mining District, lies along the same geological trend as Osisko Development's projects, suggesting the possibility of tapping into similar high-grade mineralization systems.

The report also underscored the strategic advantages of the property's location, infrastructure, and proximity to Highway 97, which reduces exploration and operational costs. Wortel detailed Golden Cariboo's drilling campaign, pointing out positive early results, such as Hole QGQ24-08, which intersected 263 meters at 0.29 g/t gold, including a higher-grade interval of 200 meters at 0.58 g/t gold. The analyst described these findings as indicative of "bulk-tonnage targets," with visible gold observed in several drill cores, bolstering the outlook for continued exploration success. [OWNERSHIP_CHART-11131]

Valuation metrics from the report included a projected fair value of CA$0.40 per share, representing a 286% potential upside from the current trading price of CA$0.14. Despite acknowledging the high risks associated with early-stage exploration projects, Couloir Capital emphasized the long-term value potential in a Tier 1 mining jurisdiction, reinforced by the company's experienced management team and promising geological trends.

Ownership and Share Structure

According to Golden Cariboo, management and insiders own 30% of Golden Cariboo Resources. President and CEO Frank Callaghan owns 16.45% or 6.93 million shares; Elaine Callaghan has 0.97% or 0.41 million shares; Director Andrew Rees has 0.79% or 0.33 million shares; and Director Laurence Smoliak has 0.3% or 0.13 million shares.

Retail investors hold the remaining. There are no institutional investors.

The company said it has 50.3 million shares outstanding, 24.83 million warrants, and 3.8 million options.

Its market cap is CA$9.7 million. Over the past 52 weeks, Golden Cariboo has traded between CA$0.08 and CA$0.36 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Golden Cariboo Resources Ltd. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Golden Cariboo Resources Ltd.
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: GCC:CSE; GCCFF:OTC; A0RLEP:WKN;3TZ:FSE, )

A new study from USGS describes a previously unknown process of marine mineral formation in the Arctic Ocean, driven by frictional heating along tectonic faults rather than by hydrothermal activity. 

Attorney General Merrick Garland ordered a pause on federal executions Thursday while the Justice Department reviews policies and procedures on capital punishment.; Credit: Win McNamee/Getty Images

Attorney General Merrick Garland has imposed a moratorium on scheduling federal executions, the Department of Justice announced on Thursday. The department will review its policies and procedures on capital punishment, following a wave of federal executions carried out under the Trump administration.

In a memo to the Justice Department, Garland justified his decision to halt the deeply controversial practice, citing factors including its capricious application and outsized impact on people of color.

"The Department of Justice must ensure that everyone in the federal criminal justice system is not only afforded the rights guaranteed by the Constitution and laws of the United States, but is also treated fairly and humanely. That obligation has special force in capital cases," Garland said in the memo.

"Serious concerns have been raised about the continued use of the death penalty across the country, including arbitrariness in its application, disparate impact on people of color, and the troubling number of exonerations in capital and other serious cases," he added. "Those weighty concerns deserve careful study and evaluation by lawmakers."

Under former President Donald Trump, the federal government carried out its first executions in a generation last year, with 13 inmates put to death in Trump's final year in office. That included an unprecedented number of federal killings carried out in the last days of his single-term presidency, bucking a nearly century-and-a-half practice of pausing capital punishments during the presidential exchange of power.

Then-Attorney General William Barr said the executions were being carried out in cases of "staggeringly brutal murders." Civil rights activists had rallied to spare the lives of those on death row. Concerns of how humanely the sentences could be carried out, as well as the recent exonerations of a number of death row inmates, were major factors in the demonstrations to cease state-sanctioned killings.

"The Department must take care to scrupulously maintain our commitment to fairness and humane treatment in the administration of existing federal laws governing capital sentences," Garland said in his memo on Thursday.

President Biden, who nominated Garland to the top law enforcement post, opposes capital punishment. During his campaign, Biden pledged to pass legislation to end the federal death penalty.

Some congressional Democrats have been working on such legislation, but no action has been taken. Some progressives and activists opposed to capital punishment had been expressing frustration that they have not seen more movement on the issue from Biden.

"A moratorium on federal executions is one step in the right direction, but it is not enough," said Ruth Friedman, director of the Federal Capital Habeas Project. "We know the federal death penalty system is marred by racial bias, arbitrariness, over-reaching, and grievous mistakes by defense lawyers and prosecutors that make it broken beyond repair."

Friedman said Biden should commute all federal death sentences, warning that a pause alone "will just leave these intractable issues unremedied and pave the way for another unconscionable bloodbath like we saw last year."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Gabriel Luna (L) and Robert Rodriguez attend the "Terminator: Dark Fate" Screening at the Alamo Drafthouse Cinema Slaughter Lane on October 29, 2019 in Austin, Texas. ; Credit: Gary Miller/Getty Images

Movie theaters are starting to reopen, and moviegoers are starting to return. All eight of the Laemmle’s theaters are now reopened, its Glendale location the last to do so a couple weeks ago. Tickets are now on sale for the first time in a year at American Cinematheque's Aero theater. 

Last weekend, “A Quiet Place: Part II” opened with very strong box office grosses. And one of the locations that sold a lot of tickets for the sequel was the Alamo Drafthouse in downtown Los Angeles. The Texas-based boutique chain filed for bankruptcy reorganization in early March. Unlike the Arclight and Pacfic theaters, Alamo was able to come back quickly with many of its theaters reopening in May.

KPCC’s John Horn called up Tim League, Alamo’s founder and executive chairman, to talk about his circuit’s return, the future of moviegoing in a streaming era, and whether or not Alamo might be a buyer of the closed Cinerama Dome in Hollywood. 

Correction: The original broadcast said that American Cinematheque announced screenings at the Rialto Theater in South Pasadena, which was a mistake. 

With contributions from John Horn 

Guest: 

Tim League, founder and executive chairman of the Alamo Drafthouse Cinema

This content is from Southern California Public Radio. View the original story at SCPR.org.

Stillwater Critical Minerals Corp. (PGE:TSX.V; PGEZF:OTCQB; J0G:FSE) has announced new assay results from its ongoing resource expansion drilling at the Stillwater West PGE-Ni-Cu-Co + Au project. Read more for detailed insights into the high-grade rhodium intercepts and resource expansion potential.

Source: Streetwise Reports 10/28/2024

Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XERTA) and its Cell Pouch technology could be the solution to existing challenges involving the delivery of medical treatments to patients, such as the ones described here.

Diabetic patients in resource-limited settings are having to revert back to one of the less favored, alternative ways to take insulin, via syringes or glass vials, because Danish pharmaceutical company, Novo Nordisk A/S (NVO:NYSE), will stop making its insulin pens, The Guardian reported. Patients generally prefer this method for dosing themselves with insulin, as shown in a 2024 survey, because it is more convenient and more accurate.

Type 1 diabetic patients already are being impacted as Novo stopped supplying its insulin pens to certain regions, South Africa for instance. Patients there have switched back to using glass vials.

In a second situation, Novo Nordisk is working to bring stem cell-based therapies to patients more efficiently and, in seeking a solution, formed a partnership with Evotec SE (EVO:NASDAQ) to develop technologies that will achieve this, noted Evotec is a Germany-based global biotech firm with its own cell therapy and partnered cell types all in preclinical development for various indications, including diabetes, oncology, cardiology, and ophthalmology.

Per the agreement, Novo Nordisk is to provide research and development funding and potentially monetary incentives to Evotec, and Evotec is to develop the desired new technologies. Novo has the option to obtain exclusive rights to use, in a predefined medical indication, the product(s) born out of this collaboration agreement. Novo's areas of focus, along with diabetes, are cardiovascular diseases, rare diseases, growth hormone-related diseases, hemophilia, nonalcoholic steatohepatitis, and weight management.

Safe, Effective Therapeutic Cell Delivery

Sernova Corp.'s Cell Pouch is a vehicle for delivering various types of therapeutic cells to patients, such as donor islet cells to insulin-dependent diabetics.

When used, the Cell Pouch's containment channels are filled with the appropriate therapeutic cells, and then the device is implanted in the patient. In situ, the cells release therapeutic proteins or hormones the patient's body completely or partially lacks. The device creates a vascularized, organ-like environment that protects the therapeutic cells from immune system attacks, keeping them alive and functioning.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote in a Sept. 12 research report.

Sernova is testing its Cell Pouch in the clinic, specifically in Type 1 diabetes. In its ongoing Phase 1/2 study, the Canadian company is evaluating the treatment of insulin-dependent diabetes with donor islets implanted via the Cell Pouch, with added immunosuppression therapy. Study data so far have shown the Cell Pouch to be safe and well tolerated and the treatment, effective, reported Dr. Joseph Pantginis, analyst at H.C. Wainwright & Co., in a Sept. 12 research report.

Seven patients, all six of Cohort A and one in Cohort B, achieved sustained insulin independence, between 5.5 and 50 months in duration, free of hypoglycemic episodes. Their blood sugar levels were controlled in the nondiabetic range (i.e.,) HbA1c less than 6.5%.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote.

A Cell Pouch removed from one of the study patients showed it still contained functioning insulin, glucagon, and somatostatin-producing cells. No evidence was seen of detrimental fibrotic tissue, too many T-cells, material degradation, or changes in the device architecture.

"We believe the impressive response rates and observed durability support Sernova's strategy and justify further investigation while positioning the technology for potential commercial success," noted Pantginis.

The results add to an expanding collection of evidence that the Cell Pouch is functioning as it should. The data also support the "impressive" results already reported from this study and help derisk future related trials.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund in a Sept. 16 note.

In another of its programs, Sernova, in collaboration with Evotec, is developing an implantable off-the-shelf, induced pluripotent stem cell (iPSC)-based islet replacement therapy, Maund reported.

"This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2)," he added.

This partnership was announced on May 17, 2022. You can read more about it in the press release here.

Market Growth Predicted to 2030

The global live cell encapsulation market, encompassing drug delivery, regenerative medicine and cell transplantation, is expected to continue growing through at least 2030, according to Grand View Research. The market's value, US$210.7 million in 2022, is forecasted to increase at a 3.97% compound annual growth rate between that year and 2030.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund.

Along with diabetes, live cell encapsulation is being used to treat neurological disorders like Parkinson's disease, The market research firm noted. Further, it has been proven to be a suitable way to deliver treatment for other types of diseases, including cancer, anemia, heart failure and more.

Several factors are expected to keep driving market growth during the forecast period, Grand View noted. A significant one is the increasing use of live cell encapsulation in regenerative medicine to replace disease or damaged tissues. A related contributor is rising public and private funding and investments in cell and gene therapies.

The advantages of live cell encapsulation in controlled drug delivery are boosting the market, too. They include enhanced therapeutic effects, lowered drug dose, reduced cytotoxicity, improved patient convenience and better patient compliance.

Novel new products and technological advancements are expected to add value to the market as well.

The Catalysts: Progress With Programs

Various potential stock-moving events are slated for Sernova, according to its September 2024 Corporate Presentation.

Two catalysts are expected by Sernova in 2025, related to the company's ongoing Phase 1/2 clinical trial in Type 1 diabetes. One is results for the remaining Cohort B patients. The other is commencement of Cohort C, who will receive, along with the islet cells, an optimized immune suppression regimen.

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

Next year, Sernova plans to start a Phase 1/2 trial of the regeneratively produced islet cells to result from its partnership with Evotec, delivered via the Cell Pouch to Type 1 diabetes patients.

Other catalysts are expected to come as a result of Sernova advancing its preclinical programs. One is a personalized treatment with patient corrected cells via Cell Pouch for hypothyroidism. Another is a Cell Pouch-delivered, ex vivo lentiviral factor VIII gene therapy for hemophilia, being developed in partnership with the European Haemacure Consortium.

Also, through partnerships, Sernova is developing technologies that would eliminate the need for concurrent immunosuppression during Cell Pouch-delivered cell treatment, a "blue sky objective," Douglas Loe, a Leede Financial Inc. analyst, noted in a Sept. 12 research report.

"Any advances in this regard could be incorporated into future Cell Pouch studies," he wrote. "We do not consider the need for such therapy to be relevant to Cell Pouch function itself."

Analyst: Company is "Very Undervalued"

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

According to H.C. Wainwright's Pantginis, the deepening responses of Type 1 diabetes patients in its Phase 1/2 trial continue to "crystallize Sernova stock's possible upside." The upside reflected in Pantginis' price target is 2,122%. The analyst recommends the company as a Buy.

Ventum's Quenneville also has a Buy on Sernova, and his target price reflects an 826% return on investment. In his report, the analyst highlighted the impressive efficacy and tolerability of the Cell Pouch up to five years post-implantation, as shown in the Phase 1/2 clinical trial data.

"This represents the longest-lasting implanted encapsulation device containing functioning islets without fibrosis," Quenneville wrote.

According to Technical Analyst Maund, Sernova is "very undervalued here given its huge potential" in the Type 1 diabetes market, as indicated on the stock charts. The fundamental outlook for the company is improving, and evidence is strong that a reversal to the upside may be happening. SVA may appreciate significantly soon. [OWNERSHIP_CHART-4790]

"Sernova is therefore viewed as a good stock to accumulate in this area, between the current price and recent lows," Maund wrote on Sept. 16. At that time, Sernova's share price was about the same as it is now.

Ownership and Share Structure

According to Refinitiv, about 12.96% of the company is held by insiders and management, and 0.05% by institutions. The rest is retail.

Top shareholders include Tomas Angel with 4.91%, Director Steven Sangha with 4.27%, Betty Anne Millar with 1.32%, Brett Alexander Whalen with 0.87%, and Garry Deol with 0.77%.

Its market cap is CA$83 M. Its 52-week range is CA$0.20−0.82 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Sernova Corp. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Corp.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

( Companies Mentioned: SVA:TSX.V;SEOVF:OTCQB;PSH:XERTA, )

Source: Dr. Jonathan Aschoff 11/07/2024

BioRestorative Therapies Inc. (BRTX:OTCBB) received a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic donor tissue for various cells, like stem, to be isolated, expanded, and cryopreserved for medical research, reported MKM analyst Dr. Jonathan Aschoff in a Nov. 5 research note.

The biotech develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

1,100% Upside Implied

Aschoff reiterated Roth's US$18 per share target price on the biotech, trading at the time of the report at about US$1.50 per share, the analyst noted. These figures reflect a potential return for investors of 1,100%.

BioRestorative Therapeutics remains a Buy.

Sources of Revenue

Aschoff discussed how BioRestorative can generate revenue. This new license is the second from NYSDOH that the biotech holds. The previous one allows it to process autologous mesenchymal stem cells, in other words, act as a tissue bank.

The U.S.-based biotech now may capitalize on its Current Good Manufacturing Practices capabilities and process, bank and distribute clinical-grade allogeneic biologics. This revenue generation would better position the biotech financially, "allowing it to reduce cash burn and dependence on equity markets," wrote Aschoff.

Another source of revenue for BioTherapeutics is from its supply agreement with Cartessa Aesthetics LLC signed earlier in 2024. Per the five-year agreement, BioTherapeutics will supply Cartessa with a preset minimum quantity of finished vials of the aesthetic company's initial cell-based biologic commercial product each year. This product, intended to reduce the appearance of fine lines and wrinkles, will be sold under the Chronos ExoCR mark. Cartessa, on the other hand, will give BioTherapeutics access to its marketing and distribution capabilities to get its technologies to aesthetic providers.

The biotech may expand the Cartessa agreement into a broader offering of biocosmeceuticals and therapeutics if future clinical trials support their approval by the U.S. Food and Drug Administration. This expansion would transform the partnership into "a vertically integrated biocosmeceutical platform," Aschoff wrote.

Clinical Trial Catalyst

Meanwhile, Aschoff reported, BioRestorative will continue its Phase 2 clinical evaluation of its novel back pain treatment, BRTX-100, in patients with chronic lumbar disc degeneration.

Preliminary results from this clinical trial are expected in late Q4/24 or early Q1/25.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Roth MKM, BioRestorative Therapies Inc., November 5, 2024

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Disclosures: Within the last twelve months, ROTH Capital Partners, or an affiliate to ROTH Capital Partners, has received compensation for investment banking services from BioRestorative Therapies, Inc.. ROTH makes a market in shares of BioRestorative Therapies, Inc. and as such, buys and sells from customers on a principal basis. Shares of BioRestorative Therapies, Inc. may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2024. Member: FINRA/SIPC.

( Companies Mentioned: BRTX:OTCBB, )

WHEN: Wed, November 18Time: 10am PT / 1pm ET  Join Now!SPONSORED BY: Nortel and AT&TJoin leading mobility experts to hear why only the mobile enterprise will survive! Join Now!Why the mobile ...

Atlas Lithium Corp. (ATLX:NASDAQ) announced that it has received the operational permit for its Neves Project. Read what this permit, unanimously approved by Minas Gerais government in Brazil, allows Atlas to do.

SEOUL, South Korea (AP) — The United States and China, the world's two biggest carbon polluters, agreed to cooperate to curb climate change with urgency, just days before President Joe Biden hosts a virtual summit of world leaders to discuss the issue.

The agreement was reached by U.S. special envoy for climate John Kerry and his Chinese counterpart Xie Zhenhua during two days of talks in Shanghai last week, according to a joint statement.

The two countries "are committed to cooperating with each other and with other countries to tackle the climate crisis, which must be addressed with the seriousness and urgency that it demands," the statement said.

China is the world's biggest carbon emitter, followed by the United States. The two countries pump out nearly half of the fossil fuel fumes that are warming the planet's atmosphere. Their cooperation is key to a success of global efforts to curb climate change, but frayed ties over human rights, trade and China's territorial claims to Taiwan and the South China Sea have been threatening to undermine such efforts.

Meeting with reporters in Seoul on Sunday, Kerry said the language in the statement is "strong" and that the two countries agreed on "critical elements on where we have to go." But the former secretary of state said, "I learned in diplomacy that you don't put your back on the words, you put on actions. We all need to see what happens."

Noting that China is the world's biggest coal user, Kerry said he and Chinese officials had a lot of discussions on how to accelerate a global energy transition. "I have never shied away from expressing our views shared by many, many people that it is imperative to reduce coal, everywhere," he said.

Biden has invited 40 world leaders, including Chinese President Xi Jinping, to the April 22-23 summit. The U.S. and other countries are expected to announce more ambitious national targets for cutting carbon emissions ahead of or at the meeting, along with pledging financial help for climate efforts by less wealthy nations.

It's unclear how much Kerry's China visit would promote U.S.-China cooperation on climate issues.

While Kerry was still in Shanghai, Chinese Vice Foreign Minister Le Yucheng signaled Friday that China is unlikely to make any new pledges at next week's summit.

"For a big country with 1.4 billion people, these goals are not easily delivered," Le said during an interview with The Associated Press in Beijing. "Some countries are asking China to achieve the goals earlier. I am afraid this is not very realistic."

During a video meeting with German and French leaders Friday, Xi said that climate change "should not become a geopolitical chip, a target for attacking other countries or an excuse for trade barriers," the official Xinhua News Agency reported.

On whether Xi would join the summit, Le said "the Chinese side is actively studying the matter."

The joint statement said the two countries "look forward to" next week's summit. Kerry said Sunday that "we very much hope that (Xi) will take part" in the summit but it's up to China to make that decision.

Biden, who has said that fighting global warming is among his highest priorities, had the United States rejoin the historic 2015 Paris climate accord in the first hours of his presidency, undoing the U.S. withdrawal ordered by predecessor Donald Trump.

Major emitters of greenhouse gases are preparing for the next U.N. climate summit taking place in Glasgow, U.K., in November. The summit aims to relaunch global efforts to keep rising global temperatures to below 1.5 degrees Celsius (2.7 degrees Fahrenheit) as agreed in the Paris accord.

According to the U.S.-China statement, the two countries would enhance "their respective actions and cooperating in multilateral processes, including the United Nations Framework Convention on Climate Change and the Paris Agreement."

It said both countries also intend to develop their respective long-term strategies before the Glasgow conference and take "appropriate actions to maximize international investment and finance in support of" the energy transition in developing countries.

Xi announced last year that China would be carbon-neutral by 2060 and aims to reach a peak in its emissions by 2030. In March, China's Communist Party pledged to reduce carbon emissions per unit of economic output by 18% over the next five years, in line with its goal for the previous five-year period. But environmentalists say China needs to do more.

Biden has pledged the U.S. will switch to an emissions-free power sector within 14 years, and have an entirely emissions-free economy by 2050. Kerry is also pushing other nations to commit to carbon neutrality by then.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Rescue workers move a stretcher containing recovered remains at the site of the collapsed Champlain Towers South condo building in Surfside, Fla., on Monday. Rescuers have recovered three more bodies and officials say the demolition of the building will accelerate search efforts.; Credit: Lynne Sladky/AP

Miami-Dade County mayor Daniella Levine Cava said on Monday morning that three more victims have been recovered from the ruins of the collapsed condo tower in Surfside, Fl., bringing the total death toll so far to 27.

Cava added that the demolition of the rest of Champlain Towers South "was executed exactly as planned" the previous evening, and that it would now allow rescue teams to work on a section of the collapsed building that was previously inaccessible. She noted that 118 individuals remain unaccounted for.

"Truly, we could not continue without bringing this building down," Cava said. "The area closest to the building was not accessible, due to the enormous risk to the team of first responders, because of the instability of the building."

According to Florida Governor Ron DeSantis, the newly accessible section of rubble is also from a part of the building where many bedrooms were located, and may contain the remains of many victims. The building collapsed in the middle of the night.

Authorities had been concerned that an approaching tropical storm might topple the standing part of the building onto the section that had already collapsed. That would have been a massive setback in the search for victims and for clues to the cause of the disaster.

Tropical Storm Elsa now appears to be tracking further to the west, and is more likely to hit the west coast of Florida, rather than the site of the disaster. But officials at the National Weather Service say the storm's course still could change.

Cava acknowledged that demolishing people's homes "is a devastating decision" and said that "our teams are doing everything possible to help those who lost their home begin to rebuild."

She said that authorities are working with insurance companies and the Federal Emergency Management Agency to streamline claims and help those who've lost homes and property.

One animal rescue volunteer had gone to court to stop the demolition of the rest of the tower, asking the court to allow more time to rescue pets that might still be trapped inside. The judge denied the motion.

Cava said in her Monday briefing that Miami-Dade rescue teams had already gone through parts of the building that were still accessible, "searching in closets and under beds" to find missing pets.

This content is from Southern California Public Radio. View the original story at SCPR.org.

When a promising new drug to treat obesity was approved by the Food and Drug Administration for sale in the U.S. last month, it was the first such treatment to gain approval since 2014.

In clinical trials, weekly injections of semaglutide — or Wegovy, as it's been branded -- helped people drop an average of 15% of their body weight. That's an average of about 34 pounds over 16 months, before their weight plateaued, a far greater weight loss, obesity specialists say, than achieved with other drugs on the market. At least as important, Wegovy raised none of the alarm bells with the FDA or obesity doctors that it might trigger serious side effects of the sort experienced by some people taking fen-phen or some previous medical treatments for obesity.

But with a price tag for Wegovy of $1,000 to $1,500 a month, a very big question remains: Will insurers cover its significant cost for the many millions of people like Marleen Greenleaf, who might benefit?

Greenleaf grew up on the island of Trinidad, where her entire family paid little heed to what they ate and paid a high medical price, she says: "My husband has diabetes, my sister has diabetes, my brother has diabetes."

Since then, she's tried — and failed — at numerous diets, says Greenleaf, now 58 and an administrator at a charter school in Washington, D.C. Then, in 2018, she signed up for the clinical trial of a new drug — a once-weekly shot that changes the way her brain signals hunger.

A drug that finally stops her cravings

She noticed the change soon after her first injection of Wegovy: "For me, there was something that triggered in my brain to tell me that I was not hungry," she says. No more fierce cravings for the chocolate chip cookies she adores. Without the cravings she was able to slow down and reconsider the foods she'd been reaching for.

"I also wanted to eat healthier," she says. "I was looking at options, reading labels, looking at the calories — not just the calories, but also the sugar."

Over the 68-week research trial, Greenleaf dropped 40 pounds. Her blood pressure fell, which meant she qualified to donate her kidney to her husband, who was on dialysis.

"It was one of the best gifts of life that I could have ever given," she says.

But after that study ended, Greenleaf regained some of the weight. Wegovy is considered a long-term, possibly lifelong medication to treat chronic obesity. In the pre-marketing clinical studies, weight loss topped out at a total average weight loss of 15-18%, even as people continued to take the drug. And, as was the case with Greenleaf, once they stopped getting the weekly injections some of that weight came back.

Now, Greenleaf wants to resume the Wegovy shots.

"My only challenge actually is getting the insurance company to approve it," she says.

Reimbursement for obesity drugs' cost is patchy

Insurance coverage, it turns out, is a giant question — not just with Wegovy, but with obesity drugs in general. Some private insurers do include some prescription obesity drugs in the list of medicines they'll cover; it's too early to tell whether Wegovy will make those lists. Many doctors and patients are optimistic, because it is a higher dose of an existing diabetes medication called Ozempic, which is often covered by insurers.

A few select state Medicaid programs will cover medications that treat obesity, in some circumstances. But, significantly, Medicare does not cover obesity drugs — and many private insurers typically follow Medicare's lead.

Yet the demand for a good treatment is there, says Dr. Fatima Cody Stanford, a leading obesity researcher at Harvard. She was not involved in conducting the Wegovy clinical trial, but closely followed it. "I'm excited about it," she says, because of the dramatic weight loss.

The drug acts on the brain so people eat less and store less of what they eat. That helps address the excess weight as well as helping with numerous related diseases of the liver or heart, for example.

Why the FDA has been slow to approve obesity treatments

There is a long history of drugs that have looked like promising treatments for obesity, then failed. Decades ago, amphetamines, were prescribed, until their addictive properties became apparent. In the 1990s, the combination of fenfluramine and phentermine — administered as the diet drug fen-phen — was heavily marketed, only to later be pulled from the market for causing heart valve problems.

Those experiences and others have made physicians skeptical.

"In obesity medicine field, we've learned to be cautiously optimistic each time we have a new medication that looks promising," says Dr. Ihuoma Eneli, director of the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital in Columbus, Ohio, who was not involved in the study of Wegovy.

So far, Eneli does not see any obvious concerns with the class of drugs that includes Wegovy, and calls the results so far "very promising." Wegovy is similar to another drug made by Novo Nordisk — Saxenda — which has been on the market since 2014, and which Eneli occasionally prescribes to her pediatric patients who are struggling with obesity.

In clinical research studies, the primary side effects reported after taking Wegovy affected the digestive system: nausea, diarrhea, vomiting, constipation, abdominal pain or intestinal infections.

Eneli says such side effects and their frequency are milder than the problems that have arisen in the past. That good safety profile may mean the drug is "less likely to come up with unanticipated risks," she says.

But, the new drug will be of little use, she and other doctors who treat obesity say, if it's not also affordable for patients.

"Before I even bring up that drug with my patients, I'm looking to see which insurance they are having on the left side of my screen — because that will determine whether I bring it up," Stanford, the Harvard physician, says. "If it's out of reach, like I said, I won't bring it up."

Stanford says her patients on existing obesity medications do extraordinary things to keep their coverage so they can afford to stay on the drugs.

"Several nurses here at the hospital that are my patients stayed working — they were supposed to retire — so they could stay on their injectable medication," Stanford says,"because that's how beneficial it was to them."

Why some are willing to pay out of pocket

Some people, like David Scheesley, 42, says he would consider paying for Wegovy, even if he had to pay the full sticker price. The Hanford, Calif., correctional officer has tried since 2019 to lose weight on various diets — low-fat, all-meat, all-vegetable — without success. His weight has led to other health concerns — with his blood fats and his heart — which makes Scheesley think of his 5-year-old son.

"I want to see him for a lot of years; I don't want to have a stroke," he says. "I don't want to have diabetes. I want to be there for him. So, for me personally, that [monetary cost] is not astronomical, if it can give me some more time."

Novo Nordisk, the company that makes Wegovy, is in talks with insurers, and acknowledges that ensuring health insurance coverage of its drug is critical. The challenge, says Douglas Langa, executive vice president of Novo Nordisk North America, is getting doctors, patients, and politicians to recognize obesity as a disease — and that therefore insurance should cover the cost of medicine to treat it.

"There's a medical component to [obesity] that needs to be recognized; this is a disease state like we should be treating any other disease state," Langa says. He says about 40% of private insurers cover Saxenda, the similar weight-loss medication the company makes.

Langa tells insurance companies this, making the case for why prescriptions for Wegovy should be covered. His company is also heavily lobbying Congress to pass legislation to allow Medicare to cover obesity medications. It makes sense from a financial perspective, he argues, because obesity is the root disease underlying so many other diseases.

"We do believe insurers understand that [untreated obesity] is a gateway into 60 other health conditions," Langa says. The need is hard to ignore, he adds. More than 100 million people in the U.S. alone struggle with obesity.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Panelists in a discussion on ‘Mobility Megatrends 2050’, highlighted that in the next decade, with electrification, autonomous driving, smart and connected infrastructure, modal diversity, and mobility that is integrated, resilient, shared, and sustainable – powered by disruptive business models, will transform and shape up of the automotive industry. The industry is racing towards a new world, driven by sustainability and changing consumer behaviour, encompassing electric vehicles, autonomous cars, mobility fleet sharing, and always connected.

Many business users have approached generative AI technology more cautiously because it can make up untrue facts and be tricked into saying unsettling things. Oracle's human resources software is used by big businesses for hiring new employees and providing performance evaluations, among other things. Oracle will put a button on many of the fields in the software that will automatically generate draft text for things like job listings or performance goals.

Microsoft-owned OpenAI has announced the general availability of its latest text-generating model GPT-4, through its API.

The Challenge is part of Small Steps to Health and Wealth�, a national Cooperative Extension program developed to motivate Americans to take action to simultaneously improve their health and personal finances. SSHW was built around a framework of 25 research-based behavior change strategies. The Challenge was originally developed in a �paper and pencil� format with printed worksheets and is now available online.

Jeff Carpenter, who will begin new duties as Cooperative Extension Director on September 1, 2010, will oversee delivery of services to meet the Extension mission of sustaining agriculture and forestry, protecting the environment, maintaining viable communities, developing responsible youth and developing strong, healthy and safe families.

Area youth participating in the NC Cooperative Extension�s 4-H program helped children at Catawba County Public Health plant vegetable seeds. The activity was one of a series of visits by local North Carolina Cooperative Extension staff and volunteers to Public Health�s Women, Infants and Children (WIC) clinic designed to encourage WIC families to grow and eat fresh vegetables.

The North Carolina Veterans Park in Fayetteville includes a visitor�s center, gardens, fountains, sculpture and displays. Five Catawba County residents, including World War II veteran Carmie Cook, had a �hand� in the park�s creation.

The Catawba County Sheriff�s Office, in conjunction with The Cognitive Connection and The Foothills Coalition, is sponsoring an Operation Pill Stoppers program that now provides fixed locations for citizens to properly dispose of their unused and unwanted medications.

Suzanne M. White, who has managed comprehensive library programs, services and personnel at two full service library branches in Rowan County for more than seven years, and has had a successful career in library services spanning more than twenty years, has been named Catawba County�s new Library Director. White succeeds Karen Foss, who will retire on February 1, 2013, after serving as the County�s Library Director since July 1999.

Some institutions have scrapped Columbus Day or switched to celebrating Indigenous Peoples' Day. One New Jersey school district came up with a new solution: eliminate all holiday names.; Credit: Olesya Semenov/EyeEm via Getty Images

Memorial Day. Thanksgiving. Labor Day.

You may be used to seeing your calendar punctuated by the various holidays that occur throughout the year.

But on one New Jersey school district's calendar, each one of these days will be listed, simply, as "day off."

It all started when the school board in Randolph Township voted to change Columbus Day to Indigenous Peoples' Day. Some residents were outraged, so the board said that instead it would wipe holiday names from the school calendar altogether while still observing the days off.

"The overwhelming majority of the township population feels that they've [Randolph Township school board members] grossly overstepped their bounds, that they're completely pushing their own personal, political ideologies," Randolph resident Tom Tatem told Fox News. He started a petition calling on school officials to resign.

Institutions across the country are wrestling with the question of what to do with Columbus Day.

Critics have derided the idea of celebrating the Italian explorer, who perpetrated violence on Native Americans when he arrived in the United States. Boosters say it is critical to recognize the contributions of Christopher Columbus, and that Italian-Americans have historically faced discrimination.

Some places have switched to marking Indigenous Peoples' Day in recognition of the Native Americans who occupied the United States long before European explorers like Columbus arrived.

Randolph Township arrived at a novel solution to this problem: eliminate every holiday name to avoid taking a side.

The goal appears to have been to sidestep the debate over Columbus Day, but the Randolph Township school system instead found itself squarely in it, and opponents of the move have called on school officials to resign.

The Randolph Board of Education is now scheduled to convene Monday for a special meeting to reconsider its plan to remove holiday names from the school calendar.

What's happening in New Jersey

In May, the Randolph school board voted unanimously to replace Christopher Columbus Day with Indigenous Peoples' Day.

Some parents grew angry with the decision, but instead of reverting back to the old calendar, the board moved in early June to scrap all holiday names from the school calendar, not giving preference to either one of the October celebrations.

"If we don't have anything on this calendar, then we don't have to have anyone [with] hurt feelings," Randolph school board member Dorene Roche said during a June 10 public meeting, according to NJ.com.

The backlash has only grown.

A petition calling on Randolph Township Schools superintendent Jennifer Fano and members of the board of education to resign has topped 4,000 signatures. "They represent everything that is wrong in education today and are completely incompetent in every aspect of their role," the petition says.

For its part, the school board acknowledged the public outcry but said its decision was misconstrued by some people.

A press release issued by the Randolph board of education on Sunday clarified that the holidays will still be observed as days off and that their decision was not meant to dishonor "the great veterans and the heroes" after which several of those holidays are named.

"These State, Federal and other holidays have not been cancelled or taken away by this Board of Education as some are falsely claiming," the board said. "Everyone is still encouraged to celebrate them in whatever way they deem appropriate."

Matthew Pfouts, director of communications and digital media for the Randolph Township Schools, told NPR the board has no further comment.

Changing views on holidays

On the national level, Columbus Day remains a federal holiday.

But a number of states, including Alaska and Virginia, as well as some cities either observe Indigenous Peoples' Day as a holiday or celebrate it in some way.

The movement away from Columbus Day has not come without controversy.

The New York City Department of Education tried to rename Columbus Day over objections and eventually settled on marking a holiday called "Italian Heritage Day/Indigenous People's Day," which drew its own set of critiques. New York Gov. Andrew Cuomo said it was wrong to make the two groups share one holiday.

There are also other efforts to recognize the role people of color played in American history.

This week, the Senate unanimously passed a bill to make Juneteenth — the day marking the end of slavery in the U.S. — a public holiday.

This content is from Southern California Public Radio. View the original story at SCPR.org.

D.C. Attorney General Karl Racine, pictured in 2019, is hoping to change how the justice system handles cases involving 16- and 17-year-olds who are charged as adults.; Credit: Claire Harbage/NPR

A new proposal from D.C. Attorney General Karl Racine could overhaul the way juveniles are charged as adults and offer greater opportunities for rehabilitation than a federal prison.

If passed, the proposal would impact people like Charlie Curtis, who was charged with armed robbery and sent to adult court at the age of 16 — a decision that he said left him confused and adrift.

Curtis said he had problems reading and writing back then, let alone asking the court to appoint him a lawyer. After his conviction, he spent years in a federal prison in New Jersey.

"It's a little bit of everything," Curtis said. "A little scary, a little nervous, you got to grow up real fast. You're not in the high school gym no more."

Curtis returned home when he was 22. It would be a while before he stabilized, got a good job driving a truck and started a family that grew to include three children. He now volunteers to help other young people leaving jail and prison — trying to offer the support he got too late.

What the legislation would change

NPR has learned Racine will introduce legislation in the D.C. Council Wednesday to ensure that 16- and 17-year-olds accused of certain crimes start in the family court system.

"Children should be treated like children, including 16- and 17-year-olds, notwithstanding the seriousness of their alleged offense," Racine said.

The proposed legislation would apply to teens charged with murder, first-degree sexual abuse, and armed robbery, among other crimes. Currently, the lead federal prosecutor in D.C. can file those kinds of cases directly in adult court — without any say from a judge — even if those defendants ultimately plead guilty to lesser charges.

D.C. has no federal prisons of its own, so young people convicted as adults can spend years in other states, at great distances from their families. The D.C. attorney general said the majority of underaged defendants charged as adults return home to the District before they are 21, but without the benefit of access to educational programs, vocational training and mentoring they could have received if their cases had been handled in the family courts.

"The adult system doesn't work that way," Racine said. "Federal Bureau of Prisons people will tell you the adult system is not made for kids."

Eduardo Ferrer, the policy director at the Georgetown Juvenile Justice Initiative, said research demonstrates charging young people in the adult system decreases public safety by making it more likely they'll break the law in the future. Most charging decisions in these cases in D.C. are made within a half a day, without the benefit of a longer review of the facts of the case and the background of the teenager, he said.

"The process in D.C. right now, because the U.S. Attorney's Office does not exercise discretion often in terms of keeping kids down in juvenile court, is more of a sledgehammer," Ferrer said. "What we really need is a scalpel."

The U.S. Attorney's Office in Washington and the Metropolitan Police Department did not return calls for comment about the proposal. But its supporters expect some resistance when it's ultimately considered by the City Council.

Ferrer pointed out that the legislation still leaves room for a judge to transfer a young person in D.C. into adult court if the judge has concerns about the ability for rehabilitation and worries about public safety. "The reality is that a young person still can be transferred to adult court," he said. "The difference is we're taking the time to get it right."

The potential impact

The vast majority — 93% — of the 16- and 17-year-olds who are charged as adults in D.C. are Black. One of them is the son of Keela Hailes. In 2008, he was charged with armed robbery. Hailes said she wasn't consulted about decisions about what was best for her son.

"It's like my son went from a 16-year-old to a 30-year-old overnight," Hailes said.

Her son was convicted and sent to federal prison in North Dakota, too far for her to visit regularly as she had done in the D.C. area. Her son, now 30 years old, is incarcerated again. Hailes said she wishes he would have had more options years ago — a chance for an education, and time spent in a juvenile facility instead of around adults in prison.

She said science suggests young people have less judgment and maturity because their brains are still developing. She thinks the new proposal will make a "huge difference" for juveniles in the legal system in the District.

The proposal is the latest in a series of steps Racine has taken to overhaul juvenile justice in D.C. He pushed the courts to stop shackling young defendants; started a restorative justice program for juveniles to meet with and make amends to victims; and worked to limit the ability of police to put handcuffs on most people under age 12.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Evidence exists linking three cancers and two other health problems with chemicals used in herbicides in the Vietnam War, a committee of the Institute of Medicine (IOM) has concluded.